Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-19-014413
Filing Date
2019-08-07
Accepted
2019-08-07 07:00:54
Documents
78
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10q.htm 10-Q 898480
2 EXHIBIT 10.1 ex10_1.htm EX-10.1 406166
3 EXHIBIT 31.1 ex31_1.htm EX-31.1 11888
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6624
  Complete submission text file 0001140361-19-014413.txt   6154435

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT rexn-20190630.xml EX-101.INS 1464013
6 XBRL TAXONOMY EXTENSION SCHEMA rexn-20190630.xsd EX-101.SCH 50941
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rexn-20190630_cal.xml EX-101.CAL 49303
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rexn-20190630_def.xml EX-101.DEF 161632
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE rexn-20190630_lab.xml EX-101.LAB 375157
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rexn-20190630_pre.xml EX-101.PRE 329590
Mailing Address 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Business Address 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850 2402685300
REXAHN PHARMACEUTICALS, INC. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 191003792
SIC: 2834 Pharmaceutical Preparations